• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Examine the Challenges and Opportunities for Investment in the Chinese Pharmaceutical Market

Posted on: Friday, 17 October 2008, 06:00 CDT

Research and Markets (http://www.researchandmarkets.com/research/e3f6f8/china_pharmaceutic) has announced the addition of the "China Pharmaceutical Market Report 2008" report to their offering.

China's pharmaceutical market is not only large and growing quickly - at almost 20% in 2007 - in the near future, it will also join the world's biggest pharmaceutical markets. This makes it strategically crucial for Western pharmaceutical companies to succeed there. However, the Chinese drug market has unique characteristics which must be understood to make the China potential a reality.

This research report contains key information on multiple important topics of the Chinese pharmaceutical market, including market data, the role of government health insurance reimbursement, government price controls, institutional purchasing practices, differing characteristics and business strategies of domestic and foreign pharmaceutical companies, and more. It also includes two appendices, one on recent acquisitions, ventures, and partnerships in the Chinese drug industry, and the other listing all drugs which Chinese government health insurance will reimburse.

This report is 34 pages. The appendices are an additional 22 pages.

Key Topics Covered:

- Introduction to China

- Overview of China Drug Market

-- Growth in Healthcare Spending

-- Pharmaceutical Sales

- Health Insurance in China

- Overview

-- Basic Medical Insurance

-- Other Public Health Insurance Systems

-- Private Health Insurance

- Drug Reimbursement System

-- Mechanics of Drug Reimbursement

-- Drug Reimbursement List

-- Who Controls Revisions to Drug Reimbursement Lists

-- When Reimbursement is Important

-- Strategies for Reimbursement List Entry

- Price Determination

- Hospital Purchasing and Prescribing

-- Hospital Tendering

-- Prescription Controls

- Foreign Pharmaceutical Companies in China

-- Overview ii. Trends

-Domestic Chinese Pharmaceutical Companies

-- Overview

-- Domestic Pharmaceutical Companies' Changing Strategies

- Pharmaceutical Distribution in China

- Predicted Trends

-- Overview

-- Healthcare Providers

-- Healthcare Funding

-- Reimbursement System

-- Price Determination

-- Regulatory Approvals

- Conclusion

Appendix A: Recent Acquisitions, Ventures, and Partnerships in the Chinese Drug Industry

Appendix B: National Reimbursement Drug List

Companies Mentioned:

AstraZeneca, Pfizer, Bayer Schering, Roche, Sanofi Aventis, Novartis, GSK, Merck, Novo Nordisk, Eli Lilly, Nycomed, Yangzijiang Pharma, Guangzhou Banyunshan Pharma, North China Pharmaceutical Co. (NCPC), Livzon Group, Wuxi Pharmatech, Apptec, Beijing Med-Pharm, Sunstone, Shanghai Rongheng Pharmaceutical Co. Ltd., Alliance Boots plc, Guangzhou Pharmaceuticals Corporation, Lenovo, Shiyao Pharmaceutical Group, Chongqing Taiji Industry, Chongqing Traditional Chinese Medicine Co., Shanghai Pharmaceutical Group, Shandong Xinhua Pharmaceutical Co., Topsun, Hubei Qianjiang Pharmaceutical Co., Beijing Weiming Kaituo Agriculture Biotechnology Co., DuPont, DSM, Zhejiang Hisun Pharmaceuticals, Jiangsu Hengrui Medicine Co., Ltd., Beijing Pharmaceutical Group Co. / BPGC, Burrill, Hubei Ready Medicine Industry Co., Warburg Pincus, Toho Pharmaceutical Co. Ltd., Jointown Group Co. Ltd

For more information visit http://www.researchandmarkets.com/research/e3f6f8/china_pharmaceutic

Source: Business Wire

More News in this Category